GSK agreed to acquire Rapt Therapeutics for $2.2 billion to gain ozureprubart, a mid‑phase anti‑IgE antibody intended to prevent food-allergy reactions. The British drugmaker will pay $58 per share and assumes global rights outside mainland China, where development remains with a Chinese partner. GSK expects Phase IIb data in 2027 and plans Phase III programs to pursue broader prophylactic use. The acquisition aims to position GSK against existing anti‑IgE therapy Xolair by offering less frequent dosing (every 8–12 weeks) and potentially expanding eligibility to patients with high IgE or high BMI who cannot use current therapy.